Keywords
Fecal microbiota transplantation
Therapeutic efficacy
Submitted : 2021-12-21
Accepted : 2022-01-05
Published : 2022-01-20
Abstract
Fecal microbiota transplantation (FMT) has been used in a wide variety of diseases. Many researchers hypothesize that the dysbiosis of intestinal microbiota plays an important role in the development of gut-derived infections; thus, FMT is a potential therapeutic target against multiple organ dysfunction syndrome (MODS). A 106-year-old male patient was initially diagnosed with cerebral infarction and pulmonary infection. During the course of hospitalization, the patient developed MODS. The patient received a single nasogastric infusion of sterile-filtered, pathogen-free feces from a healthy donor. Fecal samples were collected every two days post-infusion to monitor changes in the microbiota composition in response to treatment. After FMT, MODS and severe diarrhea were alleviated; the patient’s fecal microbiome diversity resembled that of the healthy donor’s fecal microbiome; moreover, his clinical symptoms improved remarkably with the changes in fecal microbiome. Additionally, no observable side effects were noted during FMT treatment. These findings warrant further investigation of FMT as a putative new therapy for treating microbiota-related diseases, such as MODS.
References
Wang J-W, Kuo C-H, Kuo F-C, et al., 2019, Fecal Microbiota Transplantation: Review and Update. J Formos Med Assoc, 118 Suppl 1: S23-S31.
Vindigni SM, Surawicz CM, 2017, Fecal Microbiota Transplantation. Gastroenterology Clinics of North America, 46(1): 171-185.
Bibbò S, Ianiro G, Gasbarrini A, et al., 2017, Fecal Microbiota Transplantation: Past, Present and Future Perspectives. Minerva Gastroenterol Dietol, 63(4): 420-430.
Laffin M, Millan B, Madsen KL, 2017, Fecal Microbial Transplantation as a Therapeutic Option in Patients Colonized with Antibiotic Resistant Organisms. Gut Microbes, 8(3): 221-224.
Zhang F, Cui B, He X, et al., 2018, Microbiota Transplantation: Concept, Methodology and Strategy for Its Modernization. Protein & Cell, 9(5): 462-473.
van Nood E, Vrieze A, Nieuwdorp M, et al., 2013, Duodenal Infusion of Donor Feces for Recurrent Clostridium Difficile. The New England Journal of Medicine, 368(5): 407-415.
Althani AA, Marei HE, Hamdi WS, et al., 2016, Human Microbiome and Its Association with Health and Diseases. Journal of Cellular Physiology, 231(8): 1688-1694.
Ramírez M, 2013, Multiple Organ Dysfunction Syndrome. Current Problems in Pediatric and Adolescent Health Care, 43(10): 273-277.
Rosenthal MD, Moore FA, 2016, Persistent Inflammation, Immunosuppression, and Catabolism: Evolution of Multiple Organ Dysfunction. Surgical Infections, 17(2): 167-172.
Wei Y, Yang J, Wang J, et al., 2016, Successful Treatment with Fecal Microbiota Transplantation in Patients with Multiple Organ Dysfunction Syndrome and Diarrhea Following Severe Sepsis. Crit Care, 20(1): 332.
Caporaso JG, Kuczynski J, Stombaugh J, et al., 2010, QIIME Allows Analysis of High-Throughput Community Sequencing Data. Nature Methods, 7(5): 335-336.
Quast C, Pruesse E, Yilmaz P, et al., 2013, The SILVA Ribosomal RNA Gene Database Project: Improved Data Processing and Web-Based Tools. Nucleic Acids Research, 41(Database issue): D590-596.
Sender R, Fuchs S, Milo R, 2016, Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans. Cell, 164(3): 337-340.
Kelly TN, Bazzano LA, Ajami NJ, et al., 2016, Gut Microbiome Associates with Lifetime Cardiovascular Disease Risk Profile Among Bogalusa Heart Study Participants. Circulation Research, 119(8): 956-964.
Klingensmith NJ, Coopersmith CM, 2016, Fecal Microbiota Transplantation for Multiple Organ Dysfunction Syndrome. Critical Care, 20(1): 398.
Krajicek E, Bohm M, Sagi S, et al., 2019, Fulminant Clostridium Difficile Infection Cured by Fecal Microbiota Transplantation in a Bone Marrow Transplant Recipient with Critical Neutropenia. ACG Case Reports Journal, 6(8): e00198.